MonoSol Rx Appoints James S. Scibetta to Board of Directors
11 Abril 2017 - 7:30AM
MonoSol Rx, a specialty pharmaceutical company leveraging its
PharmFilm® technology to develop and bring to market products that
improve patient outcomes and address unmet needs, today announced
the appointment of James S. Scibetta to the company’s board of
directors.
Mr. Scibetta brings a wealth of specialty pharmaceutical
industry experience to the MonoSol Rx board of directors. In
his current role as President of Pacira Pharmaceuticals
(Nasdaq:PCRX), he oversees the day-to-day operations of the
Customer and Patient Solutions group, and its commercial activities
related to the flagship product EXPAREL®, and also directs the
company’s Science Center Campus and UK entity activities related to
manufacturing, technology transfer and R&D. From 2008
through May 2016, Mr. Scibetta was CFO, and he led the company’s
IPO in 2011. As part of the executive team at Pacira, Mr.
Scibetta helped the company transition from a business model
centered around royalty-based licensing of a drug delivery
technology, into a fully integrated developer of proprietary
commercialized products. Mr. Scibetta also serves on the Board of
Matinas BioPharma (NYSE:MTNB), a clinical stage specialty pharma
company using its proprietary, lipid-crystal, nanoparticle delivery
technology to provide oral administration of anti-infective
medicines which today are only able to be delivered
intravenously,
Before joining Pacira, Mr. Scibetta was CFO of Bioenvision Inc.
(Nasdaq:BIVN) where he was instrumental in completing the $345
million sale of the company to Genzyme Corporation, and he was CFO
of Merrimack Pharmaceuticals Inc. Additionally, Mr. Scibetta
has spent more than a decade in investment banking, where he
sourced and executed transactions for a broad base of public and
private healthcare and life sciences companies. Mr. Scibetta
received his Bachelor of Science in Physics from Wake Forest
University and a Master of Business Administration from the
University of Michigan.
“Jim offers several decades of knowledge and experience to our
company’s board, and his contributions will be important to the
company’s continued growth,” said Keith Kendall, CEO of MonoSol Rx.
“We look forward to Jim’s added perspective as MonoSol Rx
transitions to developing and commercializing its own set of
proprietary products. Jim’s experience is a great fit for
where we see the future of the company.”
“I am pleased to join the board of directors at MonoSol Rx and
look forward to working closely with the board and management team
to extend the company’s reach into new market segments,” said James
Scibetta, President of Pacira. “The company’s growing portfolio of
commercial and development stage products have the potential to
offer a better delivery option, underpinned by MonoSol Rx’s best-in
class technology, for patients suffering from a variety of
diseases.”
About MonoSol Rx MonoSol Rx is a specialty
pharmaceutical company leveraging its proprietary PharmFilm
technology to develop products that improve patient outcomes and
address unmet needs. PharmFilm can benefit patients by
improving the efficacy, safety, and compliance of pharmaceutical
products. MonoSol Rx's leadership in film drug technology is
supported by strong IP protection, a robust pipeline of
prescription drug formulations, and two FDA-approved products —
Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz®
(ondansetron) oral soluble film. For press releases and other
company information, visit www.monosolrx.com.
Contact
MonoSol Rx
Jessica Patel
jpatel@monosolrx.com
The Ruth Group
Lee Roth
lroth@theruthgroup.com
(646) 536-7012
Bioenvision (NASDAQ:BIVN)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Bioenvision (NASDAQ:BIVN)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024